MATEUS MISTIERI SIMABUKURO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
bookPart Neoplasias benignas e malignas do sistema nervoso central(2021) STERMAN NETO, Hugo; NEVILLE, Iuri Santana; SIMABUKURO, Mateus MistieribookPart Neoplasias do sistema nervoso central: aspectos diagnósticos e terapêuticos(2021) STERMAN NETO, Hugo; NEVILLE, Iuri Santana; SIMABUKURO, Mateus Mistieri- Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease(2021) GAIG, Carles; COMPTA, Yaroslau; HEIDBREDER, Anna; MARTI, Maria J.; TITULAER, Maarten J.; CRIJNEN, Yvette; HOEGL, Birgit; LEWERENZ, Jan; ERRO, Maria Elena; GARCIA-MONCO, Juan Carlos; NIGRO, Pasquale; TAMBASCO, Nicola; PATALONG-OGIEWA, Maja; ERDLER, Marcus; MACHER, Stefan; BERGER-SIECZKOWSKI, Evelyn; HOEFTBERGER, Romana; GEIS, Christian; HUTTERER, Markus; MILAN-TOMAS, Angela; MARTIN-BASTIDA, Antonio; MANZANARES, Lydia Lopez; QUINTAS, Sonia; HOEGLINGER, Guenter U.; MOEHN, Nora; SCHOEBERL, Florian; THALER, Franziska S.; ASIOLI, Gian Maria; PROVINI, Federica; PLAZZI, Giuseppe; BERGANZO, Koldo; BLAABJERG, Morten; BRUEGGEMANN, Norbert; FARIAS, Tarsis; NG, Chen Fei; GIORDANA, Caroline; MARTIN, Alejandro Herrero-San; HUEBRA, Lucio; KOTSCHET, Katya; LIENDL, Herburg; MONTOJO, Teresa; MORATA, Carlos; PEREZ, Jesus Perez; PUERTAS, Inmaculada; SEIFERT-HELD, Thomas; SEITZ, Caspar; SIMABUKURO, Mateus Mistieri; TELLEZ, Nieves; VILLACIEROS-ALVAREZ, Javier; WILLEKENS, Barbara; SABATER, Lidia; IRANZO, Alex; CANO, Joan Santamaria; DALMAU, Josep; GRAUS, FrancescBackground and Objectives Anti-IgLON5 disease is a recently described neurologic disease that shares features of autoimmunity and neurodegeneration. Abnormal movements appear to be frequent and important but have not been characterized and are underreported. We describe the frequency and types of movement disorders in a series of consecutive patients with this disease. Methods In this retrospective, observational study, the presence and phenomenology of movement disorders were assessed with a standardized clinical questionnaire. Available videos were centrally reviewed by 3 experts in movement disorders. Results Seventy-two patients were included. In 41 (57%), the main reason for initial consultation was difficulty walking along with one or several concurrent movement disorders. At the time of anti-IgLON5 diagnosis, 63 (87%) patients had at least 1 movement disorder with a median of 3 per patient. The most frequent abnormal movements were gait and balance disturbances (52 patients [72%]), chorea (24 [33%]), bradykinesia (20 [28%]), dystonia (19 [26%]), abnormal body postures or rigidity (18 [25%]), and tremor (15 [21%]). Other hyperkinetic movements (myoclonus, akathisia, myorhythmia, myokymia, or abdominal dyskinesias) occurred in 26 (36%) patients. The craniofacial region was one of the most frequently affected by multiple concurrent movement disorders (23 patients [32%]) including dystonia (13), myorhythmia (6), chorea (4), or myokymia (4). Considering any body region, the most frequent combination of multiple movement disorders consisted of gait instability or ataxia associated with craniofacial dyskinesias or generalized chorea observed in 31 (43%) patients. In addition to abnormal movements, 87% of patients had sleep alterations, 74% bulbar dysfunction, and 53% cognitive impairment. Fifty-five (76%) patients were treated with immunotherapy, resulting in important and sustained improvement of the movement disorders in only 7 (13%) cases. Discussion Movement disorders are a frequent and leading cause of initial neurologic consultation in patients with anti-IgLON5 disease. Although multiple types of abnormal movements can occur, the most prevalent are disorders of gait, generalized chorea, and dystonia and other dyskinesias that frequently affect craniofacial muscles. Overall, anti-IgLON5 disease should be considered in patients with multiple movement disorders, particularly if they occur in association with sleep alterations, bulbar dysfunction, or cognitive impairment.
bookPart Encefalites imunomediadas e síndromes neurológicas paraneoplásicas(2021) SIMABUKURO, Mateus Mistieri- Reply to: Comparing VUS and AUS: Parallels and Differences in Neurogenetics and Neuroimmunology(2021) PEDROSO, Jose Luiz; SILVA, Thiago Yoshinaga Tonholo; SIMABUKURO, Mateus M.; ROSA, Augusto Braganca Reis; BARSOTTINI, Orlando G.
- Encephalitis with Autoantibodies against the Glutamate Kainate Receptors GluK2(2021) LANDA, Jon; GUASP, Mar; MIGUEZ-CABELLO, Federico; GUIMARAES, Joana; MISHIMA, Takayasu; ODA, Fumiko; ZIPP, Frauke; KRAJINOVIC, Vladimir; FUHR, Peter; HONNORAT, Jerome; TITULAER, Maarten; SIMABUKURO, Mateus; PLANAGUMA, Jesus; MARTINEZ-HERNANDEZ, Eugenia; ARMANGUE, Thais; SAIZ, Albert; GASULL, Xavier; SOTO, David; GRAUS, Francesc; SABATER, Lidia; DALMAU, JosepObjective The objective of this study was to report the identification of antibodies against the glutamate kainate receptor subunit 2 (GluK2-abs) in patients with autoimmune encephalitis, and describe the clinical-immunological features and antibody effects. Methods Two sera from 8 patients with similar rat brain immunostaining were used to precipitate the antigen from neuronal cultures. A cell-based assay (CBA) with GluK2-expressing HEK293 cells was used to assess 596 patients with different neurological disorders, and 23 healthy controls. GluK2-ab effects were determined by confocal microscopy in cultured neurons and electrophysiology in GluK2-expressing HEK293 cells. Results Patients' antibodies precipitated GluK2. GluK2 antibody-specificity was confirmed by CBA, immunoprecipitation, GluK2-immunoabsorption, and GluK2 knockout brain immunohistochemistry. In 2 of 8 samples, antibodies reacted with additional GluK2 epitopes present in GluK1 or GluK3; in both, the reactivity was abrogated after GluK2 immuno-absorption. Six of 8 patients developed acute encephalitis and clinical or magnetic resonance imaging (MRI) features of predominant cerebellar involvement (4 presenting as cerebellitis, which in 2 patients caused obstructive hydrocephalus), and 2 patients had other syndromes (1 with cerebellar symptoms). One of the samples showed mild reactivity with non-kainate receptors (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors [AMPAR] and N-methyl-D-aspartate receptors [NMDAR]) leading to identify 6 additional cases with GluK2-abs among patients with anti-AMPAR (5/71) or anti-NMDAR encephalitis (1/73). GluK2-abs internalized GluK2 in HEK293 cells and neurons; these antibody-effects were reversible in neurons. A significant reduction of GluK2-mediated currents was observed in cells treated with patients' GluK2 serum following the time frame of antibody-mediated GluK2 internalization. Interpretation GluK2-abs associate with an encephalitis with prominent clinicoradiological cerebellar involvement. The antibody effects are predominantly mediated by internalization of GluK2. ANN NEUROL 2021
- Thymoma and Autoimmune Encephalitis Clinical Manifestations and Antibodies(2021) GUASP, Mar; LANDA, Jon; MARTINEZ-HERNANDEZ, Eugenia; SABATER, Lidia; IIZUKA, Takahiro; SIMABUKURO, Mateus; NAKAMURA, Masataka; KINOSHITA, Makoto; KURIHARA, Masanori; KAIDA, Kenichi; BRUNA, Jordi; KAPETANOVIC, Solange; SANCHEZ, Pedro; RUIZ-GARCIA, Raquel; NARANJO, Laura; PLANAGUMA, Jesus; MUNOZ-LOPETEGI, Amaia; BATALLER, Luis; SAIZ, Albert; DALMAU, Josep; GRAUS, FrancescObjective To report the clinical, neuroimaging, and antibody associations in patients with autoimmune encephalitis (AE) and thymoma. Methods A retrospective cohort study of 43 patients was conducted. Antibody determination and immunoprecipitation to characterize novel antigens were performed using reported techniques. Results Patients' median age was 52 years (range: 23-88 years). Forty (93%) had neuronal surface antibodies: gamma-aminobutyric acid receptor A (GABA(A)R) (15), amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) (13), contactin-associated protein-like 2 (CASPR2) (4), leucine-rich, glioma inactivated 1 (LGI1) (3), glycine receptor (GlyR) (3), and unknown antigens (2). Concurrent antibodies against intracellular antigens occurred in 13 (30%; 9 anti-collapsin response mediator protein 5 [CRMP5]) and were more frequent in anti-AMPAR encephalitis (54% vs 20%; p = 0.037). The most common clinical presentation was encephalitis with multiple T2/fluid-attenuated inversion recovery hyperintense lesions in 23 (53%) patients (15 GABA(A)R, 5 AMPAR, and 1 unknown neuropil antibody), followed by encephalitis with peripheral nerve hyperexcitability in 7 (16%; 4 CASPR2, 2 LGI1, and 1 unknown antibody), limbic encephalitis in 6 (14%; 4 AMPAR, 1 LGI1, and 1 antibody negative), progressive encephalomyelitis with rigidity and myoclonus in 4 (9%; 3 GlyR and 1 AMPAR antibodies), and encephalitis with normal MRI in 3 (7%; AMPAR antibodies). Anti-GABA(A)R encephalitis was more prevalent in Japanese patients compared with Caucasians and other ethnicities (61% vs 16%; p = 0.003). In anti-AMPAR encephalitis, 3/4 patients with poor and 0/6 with good outcome had concurrent CRMP5 antibodies (p = 0.033). Immunoprecipitation studies identified metabotropic glutamate receptor 3 antibodies that were additionally found in 5 patients (3 with and 2 without encephalitis). Conclusions AE in patients with thymoma include several clinical-radiologic syndromes that vary according to the associated antibodies. Anti-GABA(A)R encephalitis was the most frequent AE and occurred more frequently in Japanese patients.
- Potential autoimmune encephalitis following yellow fever vaccination: A report of three cases(2021) GUEDES, Bruno Fukelmann; RIBEIRO, Ana Freitas; PINTO, Lecio Figueira; VIDAL, Jose Ernesto; OLIVEIRA, Fernanda Gurgel de; SZTAJNBOK, Jaques; OLIVEIRA, Augusto Cesar Penalva de; SIMABUKURO, Mateus MistieriMeningoencephalitis following yellow fever vaccination is considered a viral neuroinvasive disease. We describe three patients with typical autoimmune encephalitis syndromes that developed 1?27 days following yellow fever vaccination. Anti-N-methyl-D-aspartate-r antibodies were identified in the CSF and serum of two patients and the other case was associated with anti-neurexin-3 antibodies. One case was confirmed as vaccine-associated neurotropic disease due to reactive CSF yellow fever IgM, which suggested an infectious-autoimmune overlap mechanism. Two aditional cases of Anti-N-methyl-D-aspartate-r encephalitis were identified in the literature review. Antibody-positive autoimmune encephalitis should be included in the differential diagnosis of neurologic adverse events following yellow fever vaccination.
- Teaching Video NeuroImages: Multisystemic Erdheim-Chester Disease Presenting as a Cerebellar Ataxia(2021) BRITO, Marcelo Houat de; OLIVEIRA, Marcos Castello Barbosa de; CASAL, Yuri Reis; ABDO, Andre Neder Ramires; LUCATO, Leandro Tavares; SIMABUKURO, Mateus Mistieri